Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
INTA: ‘Davos of IP’ will take London meeting to a ‘different level’
Europe
Excitement is mounting for the world’s largest IP gathering, which will see the industry’s elites travelling to the UK in the spring, reveals the association’s CEO.   5 February 2026
Nine-partner litigation team leaves Winston & Strawn
Careers
The trial group, which brings “exceptional litigation talent”, joins larger firm in Texas and Washington, DC, coinciding with the announcement of the Winston Taylor merger.   5 February 2026
Squire Patton Boggs brings in tech and data expert as Ireland practice lead
Careers
The new hire, who has clients in pharma and medical devices and diagnostics, will lead the Dublin office's IP & Technology practice.   4 February 2026
Americas
Nominations are open for the Life Sciences Patent Network's 2026 awards in Boston, including six new categories and winners selected by leading industry experts.   3 February 2026
Europe
As legislative activity in life sciences increases, in-house teams are struggling to keep up. Experts share their sources and strategies for monitoring developments, coordinating internally, and knowing when to engage.   3 February 2026
Careers
The third European life sciences hire in recent months brings in-house regulatory expertise from Moderna in Munich.   2 February 2026
Careers
The seasoned IP leader has left biotech GRAIL to expand the firm’s capabilities in life sciences, technology, and AI in California.   2 February 2026
Careers
Transatlantic ‘powerhouse’ Winston Taylor is set to launch in May 2026, with a particular focus on technology, life sciences and transatlantic services.   30 January 2026
Careers
Melbourne-based firm adds senior attorney with over 25 years of experience in therapeutics, diagnostics and biologics as demand for specialist patent services rises.   29 January 2026
Americas
A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.   29 January 2026